KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Long-Term Investments (2017 - 2022)

Palvella Therapeutics has reported Long-Term Investments over the past 5 years, most recently at $4.5 million for Q2 2022.

  • Quarterly Long-Term Investments changed N/A to $4.5 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Jun 2022, changed N/A year-over-year, with the annual reading at $7.5 million for FY2018, 24.23% down from the prior year.
  • Long-Term Investments was $4.5 million for Q2 2022 at Palvella Therapeutics, down from $6.8 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $29.0 million in Q1 2020 and troughed at $700000.0 in Q2 2018.
  • The 4-year median for Long-Term Investments is $5.6 million (2020), against an average of $8.2 million.
  • Year-over-year, Long-Term Investments dropped 24.23% in 2018 and then soared 385.13% in 2019.
  • A 4-year view of Long-Term Investments shows it stood at $7.5 million in 2018, then surged by 66.68% to $12.5 million in 2019, then tumbled by 46.13% to $6.8 million in 2020, then plummeted by 32.74% to $4.5 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Long-Term Investments are $4.5 million (Q2 2022), $6.8 million (Q3 2020), and $1.6 million (Q2 2020).